Paula Ragan Sells 31,897 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CEO Paula Ragan sold 31,897 shares of the business’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $0.56, for a total transaction of $17,862.32. Following the completion of the transaction, the chief executive officer now directly owns 1,025,816 shares of the company’s stock, valued at approximately $574,456.96. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Paula Ragan also recently made the following trade(s):

• On Monday, October 7th, Paula Ragan sold 239,436 shares of X4 Pharmaceuticals stock. The shares were sold at an average price of $0.55, for a total value of $131,689.80.

X4 Pharmaceuticals Trading Down 4.3 %

NASDAQ:XFOR traded down $0.02 during mid-day trading on Wednesday, hitting $0.53. The company had a trading volume of 1,754,595 shares, compared to its average volume of 2,108,026. The firm has a market cap of $89.51 million, a P/E ratio of -0.80 and a beta of 0.36. X4 Pharmaceuticals, Inc. has a fifty-two week low of $0.47 and a fifty-two week high of $1.60. The business’s fifty day moving average is $0.66 and its two-hundred day moving average is $0.86. The company has a debt-to-equity ratio of 0.79, a quick ratio of 6.04 and a current ratio of 6.07.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.03). The company had revenue of $0.56 million for the quarter, compared to analysts’ expectations of $52.98 million. During the same period in the prior year, the company posted ($0.33) EPS. As a group, research analysts expect that X4 Pharmaceuticals, Inc. will post -0.65 earnings per share for the current year.

Institutional Investors Weigh In On X4 Pharmaceuticals

Large investors have recently modified their holdings of the business. SG Americas Securities LLC acquired a new position in shares of X4 Pharmaceuticals in the third quarter valued at approximately $37,000. AQR Capital Management LLC lifted its position in shares of X4 Pharmaceuticals by 1,080.3% in the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock worth $246,000 after purchasing an additional 388,115 shares in the last quarter. K2 Principal Fund L.P. acquired a new position in X4 Pharmaceuticals during the second quarter worth $284,000. Ensign Peak Advisors Inc grew its position in X4 Pharmaceuticals by 4.6% in the second quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock valued at $1,477,000 after purchasing an additional 111,032 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in X4 Pharmaceuticals in the 2nd quarter valued at $65,000. 72.03% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of X4 Pharmaceuticals in a research note on Friday, June 28th.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.